source
- Chiesi to acquire KalVista for $1.9 billion, adding hereditary angioedema pill to rare-disease portfolioItalian pharmaceutical group Chiesi announced it will purchase KalVista Therapeutics for $1.9 billion. The transaction values KalVista at $27 per share, a 40 percent premium to its last closing pri…
- GSK CEO warns possible team reorganization if upcoming Phase 3 readouts fall shortGSK's chief executive Luke Miels told analysts during the first‑quarter earnings call that the company has several pivotal Phase 3 trials slated for this year. He said that if those late‑stage rea…